What Is WAC Pricing in Pharmacy? (And Why It Matters for Independent Pharmacies)

If you have spent any time reviewing drug invoices or comparing pricing benchmarks, you have probably seen the abbreviation WAC. It shows up in contracts, reimbursement schedules, and distributor pricing sheets. But what does it actually mean, and how does it affect what your pharmacy pays?

What WAC Stands For

WAC stands for Wholesale Acquisition Cost. It is the manufacturer's list price for a drug when sold to wholesalers or direct purchasers, not including rebates, chargebacks, or other price adjustments negotiated after the fact.

WAC is set by the drug manufacturer, not by the wholesaler or distributor. It functions as a starting point, a published list price from which actual transaction prices are often negotiated down, depending on the buyer's volume, contract terms, and relationship with the distributor.

Why WAC Is Not What Most Pharmacies Actually Pay

For large chain pharmacies and buying groups with significant negotiating leverage, actual acquisition costs are often well below WAC. They receive rebates, contract pricing, and volume discounts that bring their effective cost down substantially.

For independent pharmacies without that leverage, the gap is smaller. Many independent pharmacies pay close to WAC, or to prices derived from WAC with modest adjustments. This structural disadvantage is one reason independent pharmacies have looked for alternative sourcing channels.

WAC vs. NADAC: What Is the Difference?

NADAC, or National Average Drug Acquisition Cost, is a benchmark published weekly by the Centers for Medicare and Medicaid Services. Unlike WAC, NADAC is based on actual invoice data collected from retail community pharmacies. It reflects what pharmacies actually paid, not what manufacturers listed.

For many drugs, NADAC runs lower than WAC. This gap is particularly notable for brand medications, where manufacturer list prices have risen significantly while actual acquisition costs, adjusted for rebates and contract pricing across the market, may be lower.

For independent pharmacies evaluating pricing, NADAC is often a more useful reference point than WAC. It reflects real-world transaction data rather than a starting list price.

How This Affects Independent Pharmacy Margins

Independent pharmacies caught paying near-WAC prices on medications face margin compression, particularly on brand drugs where reimbursement rates from PBMs and insurers may be set with larger, lower-cost buyers in mind.

Finding acquisition costs closer to NADAC, or below it when market conditions allow, can make a meaningful difference in profitability per fill.

How Peer-to-Peer Sourcing Fits In

One option independent pharmacies have used to access better pricing on specific medications is peer-to-peer sourcing through platforms like InStockRx. When a pharmacy has surplus brand inventory and needs to move it, they may list it at a price below WAC and closer to NADAC, or even below it on short-dated stock. Buyers get access to pricing they may not have through their primary distributor on those specific items.

This does not replace primary distribution. But for fill-ins, surplus brand inventory, or specific medications where your distributor is out of stock, it is a practical alternative that operates within DSCSA compliance requirements.

The Bottom Line

WAC is a list price, not a transaction price. For independent pharmacies, understanding the gap between WAC and what you are actually paying, compared to NADAC as a real-world benchmark, is a useful starting point for evaluating whether your acquisition costs are competitive.